TRAVERE THERAPEUTICS, INC. Finite-Lived Intangible Assets, Accumulated Amortization
TRAVERE THERAPEUTICS, INC. (TVTX) had Finite-Lived Intangible Assets, Accumulated Amortization of $208.97 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-08-04
- 2026-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $208.97M.
- 2026-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $205.15M.
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $180.35M.
- 2025-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $162.61M.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization | Finite-Lived Intangible Assets, Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $208.97M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $205.15M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $180.35M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $162.61M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $147.20M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $133.52M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $121.07M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $109.41M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $98.60M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $88.70M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $79.35M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $89.82M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $181.16M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $167.82M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $62.46M 10-K · filed 2024-02-20 | $158.83M 10-K · filed 2023-02-23 |
| 2022-09-30 | $158.25M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $150.36M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $142.79M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $136.06M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $129.72M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $123.38M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $117.18M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $111.49M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $105.32M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $99.07M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $93.71M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $88.60M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $83.40M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $78.52M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $73.62M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $68.95M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $64.28M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $59.67M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $55.31M 10-Q · filed 2018-07-06 | |
| 2017-12-31 | $51.05M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $46.68M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $42.11M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $37.69M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $33.50M 10-K · filed 2018-07-06 | |
| 2016-09-30 | $29.42M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $25.36M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $21.45M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $17.56M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $13.75M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $10.73M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $6.92M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $5.60M 10-K · filed 2016-02-26 | $5.60M 10-K · filed 2015-03-11 |
| 2014-09-30 | $3.79M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$1.98M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $323.98K 10-K/A · filed 2015-07-09 | -$323.98K 10-K · filed 2014-03-28 |
| 2012-12-31 | $121.38K 10-K/A · filed 2015-07-09 | -$121.38K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |